Guowu Wu

519 total citations
8 papers, 26 citations indexed

About

Guowu Wu is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Guowu Wu has authored 8 papers receiving a total of 26 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Guowu Wu's work include Cancer therapeutics and mechanisms (2 papers), Glioma Diagnosis and Treatment (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Guowu Wu is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Glioma Diagnosis and Treatment (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Guowu Wu collaborates with scholars based in China. Guowu Wu's co-authors include Jiaquan Li, Heming Wu, Zhengguang Zhu, Ying Jiang, Siming Liu, Jiajie Zhang, Chuan Huang, Shanhe Wan, Ruichao Zeng and Yifan Kong and has published in prestigious journals such as Journal of Clinical Oncology, Bioorganic & Medicinal Chemistry and Frontiers in Oncology.

In The Last Decade

Guowu Wu

7 papers receiving 26 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guowu Wu China	3	14	13	8	5	4	8	26
Nuntana Dinglasan United States	2	19 1.4×	19 1.5×	7 0.9×	8 1.6×	5 1.3×	5	35
Lizhu Lin China	3	22 1.6×	11 0.8×	11 1.4×	5 1.0×	4 1.0×	5	30
Dazhi Xu China	3	10 0.7×	14 1.1×	14 1.8×	4 0.8×	6 1.5×	6	32
Elen Höglander United Kingdom	4	19 1.4×	13 1.0×	10 1.3×	9 1.8×	6 1.5×	5	32
Sophia Schuman United States	2	18 1.3×	21 1.6×	14 1.8×	5 1.0×	4 1.0×	5	38
Gloryanne Aidoo-Micah United Kingdom	3	9 0.6×	12 0.9×	7 0.9×	6 1.2×	2 0.5×	4	25
Fanny Wunder United States	3	8 0.6×	8 0.6×	10 1.3×	10 2.0×	4 1.0×	10	20
Tomonari Cho Japan	2	14 1.0×	8 0.6×	6 0.8×	7 1.4×	3 0.8×	3	25
Reyes Gonzalez-Exposito Spain	4	19 1.4×	17 1.3×	10 1.3×	7 1.4×	8 2.0×	4	43
Isobel J. Fetter United States	2	11 0.8×	13 1.0×	3 0.4×	4 0.8×	4 1.0×	3	20

Countries citing papers authored by Guowu Wu

Since Specialization

Citations

This map shows the geographic impact of Guowu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guowu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guowu Wu more than expected).

Fields of papers citing papers by Guowu Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guowu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guowu Wu. The network helps show where Guowu Wu may publish in the future.

Co-authorship network of co-authors of Guowu Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Guowu Wu. A scholar is included among the top collaborators of Guowu Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guowu Wu. Guowu Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Wang, Jie, Rui Wan, Lin Wu, et al.. (2025). A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3025–3025. 1 indexed citations

Zhou, Chenfei, Jinling Jiang, Xiaojun Xiang, et al.. (2024). Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors. Experimental Hematology and Oncology. 13(1). 98–98. 1 indexed citations

Wu, Guowu, Yong Lin, Yongxin Chen, et al.. (2024). Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma. Bioorganic Chemistry. 153. 107905–107905. 1 indexed citations

Yi, Lilan, et al.. (2024). Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review. Frontiers in Oncology. 14. 1442605–1442605.

Jiang, Ying, Chunhui Huang, Guowu Wu, et al.. (2023). A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma. Pharmaceutics. 15(5). 1501–1501. 5 indexed citations

Li, Jiaquan, et al.. (2023). KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer. International Journal of General Medicine. Volume 16. 4109–4120. 11 indexed citations

Liu, Siming, Chuan Huang, Chunhui Huang, et al.. (2023). Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 ^G2032R and ALK ^G1202R. Journal of Enzyme Inhibition and Medicinal Chemistry. 38(1). 2227779–2227779. 6 indexed citations

Yang, Zichao, Guowu Wu, Mingxia Li, et al.. (2023). Discovery of conformationally constrained c-Abl inhibitors with potential neuroprotective effects against Parkinson’s disease. Bioorganic & Medicinal Chemistry. 96. 117532–117532. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact